Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIB7734 (Daxdilimab) for Moderate to Severe SLE
NCT04925934Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of daxdilimab in systemic lupus erythematosus (SLE), sponsored by Amgen. Started May 2021; status: completed.
02
Drugs
daxdilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04925934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925934.